ArticleTranslational oncology2026
USP48 functions as a suppressor of colorectal cancer via SELENBP1 stabilization.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimColorectal cancer (CRC) is a leading cause of cancer-related death. SELENBP1 is a tumor suppressor in CRC. However, the mechanism regulating the stability of the SELENBP1 protein remains elusive.
methodsHere, we explored multiple ubiquitin-specific proteases (USPs) that may control SELENBP1 stability. In vitro, USP48 was overexpressed in CRC cell lines to observe its effect on malignant behaviors of cells. The interaction between USP48 and SELENBP1 was investigated using immunoprecipitation.
resultsOur data showed that USP48 exhibits a robust effect in stabilizing SELENBP1. Results of bioinformatics analysis showed that although USP48 expression was variable across datasets, its prognostic signal was consistent, and it was positively correlated with the prognosis of CRC patients. USP48 expression is also decreased in multiple CRC cells, and overexpression of USP48 impaired the malignant behaviors and stemness of HCT-116 and LOVO CRC cells. At the molecular level, USP48 interacts with SELENBP1 in CRC cells. USP48 overexpression substantially decreased the ubiquitination level of SELENBP1 and enhanced its stability. Depletion of SELENBP1 in USP48-overexpressing CRC cells improved their malignant behaviors and stemness, suggesting that SELENBP1 is a key factor in mediating the tumor suppressor function of USP48 in CRC.
conclusionTogether, these observations deepen our understanding of the post-translational regulation of SELENBP1 and underscore the diagnostic and therapeutic potential of the USP48-SELENBP1 axis in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.